AI Article Synopsis
- The STEP study investigated why individuals with adenovirus serotype 5 (Ad5) antibodies who received an HIV vaccine might have an increased risk of HIV-1.
- Research found that the presence of Ad5-specific neutralizing antibodies didn't correlate with T cell responses, indicating that having these antibodies doesn't guarantee a stronger immune response.
- The study challenges the idea that heightened T cell activity in Ad5-seropositive individuals led to increased susceptibility to HIV-1 following vaccination.
Article Abstract
The immunologic basis for the potential enhanced HIV-1 acquisition in adenovirus serotype 5 (Ad5)-seropositive individuals who received the Merck recombinant Ad5 HIV-1 vaccine in the STEP study remains unclear. Here we show that baseline Ad5-specific neutralizing antibodies are not correlated with Ad5-specific T lymphocyte responses and that Ad5-seropositive subjects do not develop higher vector-specific cellular immune responses as compared with Ad5-seronegative subjects after vaccination. These findings challenge the hypothesis that activated Ad5-specific T lymphocytes were the cause of the potential enhanced HIV-1 susceptibility in the STEP study.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2756115 | PMC |
| http://dx.doi.org/10.1038/nm.1991 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!